86 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain
8-K
EX-99.1
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations
8-K
EX-99.1
VXRT
Vaxart Inc
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations
8-K
EX-99.1
VXRT
Vaxart Inc
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain
8-K
EX-99.1
b8oy0caa9 vwayg
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
orkere8h4f
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
glzj4te
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
197kdlwnmxumx
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
w6ew499k 1qr
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
w1iuts1j4buuk5c ns0
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
r7fzv0qayb mwm
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
o8j s38o63
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-99.1
xdwup15tc0
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.2
zi27s cukp5
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
k814dcnvrfq
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
EX-99.1
7j6 c3uhl74x
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
8-K
EX-99.1
ieju 4n16
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm
8-K
EX-99.1
2fn92lwfur 8ez
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
8-K
EX-99.1
t4wjanq5
8 Aug 22
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
4:06pm